James R Priest1, Wei Yang2, Gerald Reaven3, Joshua W Knowles3, Gary M Shaw2. 1. Stanford Cardiovascular Institute, Division of Pediatric Cardiology, Stanford University School of Medicine, Stanford, California. 2. Department of Pediatrics, Stanford University School of Medicine, Stanford, California. 3. Stanford Cardiovascular Institute, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California.
Abstract
IMPORTANCE: There is a well-described association between maternal diabetes mellitus and risk of congenital heart disease (CHD) in offspring. Although the clinical diagnoses of type 2 diabetes or gestational diabetes are strong risk factors for CHD, subclinical abnormalities of glucose and insulin metabolism are common within the general population and could also confer risk for CHD. We hypothesize that continuous measures of blood analytes related to maternal diabetes are related to odds of cardiac malformations. OBJECTIVE: To explore the potential association of 2 different CHD phenotypes in offspring with maternal midpregnancy measures of glucose and insulin. DESIGN, SETTING, AND PARTICIPANTS: Case-control study from a population-based cohort of 277 pregnant women in southern and central California carrying infants with tetralogy of Fallot (TOF) (n = 55), dextrotransposition of the great arteries (dTGA) (n = 42), or healthy infants without CHD (n = 180). Serum samples were collected from 2003 through 2007. The analysis was conducted from March through June 2015. MAIN OUTCOMES AND MEASURES: Blood analytes related to maternal glucose metabolism were measured from random nonfasting second-trimester blood samples. We measured serum insulin levels by a validated radioimmunoassay, and we measured glucose levels. Multivariable logistic regression models estimated the association between these levels and case status. RESULTS: Serum glucose values were elevated in the maternal samples for offspring with TOF (median, 97.0 mg/dL [to convert to millimoles per liter, multiply by 0.0555]) relative to controls (median, 91.5 mg/dL) (P = .01, Wilcoxon rank sum test), a phenomenon not observed in the maternal samples for offspring with dTGA (median, 90.0 mg/dL) relative to controls (P = .18, Wilcoxon rank sum test). Serum insulin levels were significantly different between controls (median, 18.8 μIU/mL [to convert to picomoles per liter, multiply by 6.945]) and maternal samples for offspring with dTGA (median, 13.1 μIU/mL; P = .048, Wilcoxon rank sum test) but not with TOF (median, 14.3 μIU/mL; P = .35, Wilcoxon rank sum test). Relative to maternal blood glucose levels of infants without cardiac malformations, we observed that maternal blood glucose levels in models including insulin were strongly associated with odds of TOF (adjusted odds ratio = 7.54; 95% CI, 2.30-24.69) but not with dTGA (adjusted odds ratio = 1.16; 95% CI, 0.28-4.79). CONCLUSIONS AND RELEVANCE: These results represent a direct correlation of glucose as a continuous variable to odds of specific cardiac malformations. The association between serum glucose and odds of TOF indicates the need for additional epidemiological and mechanistic investigations into the risk conferred by insulin signaling and glucose metabolism during early pregnancy.
IMPORTANCE: There is a well-described association between maternal diabetes mellitus and risk of congenital heart disease (CHD) in offspring. Although the clinical diagnoses of type 2 diabetes or gestational diabetes are strong risk factors for CHD, subclinical abnormalities of glucose and insulin metabolism are common within the general population and could also confer risk for CHD. We hypothesize that continuous measures of blood analytes related to maternal diabetes are related to odds of cardiac malformations. OBJECTIVE: To explore the potential association of 2 different CHD phenotypes in offspring with maternal midpregnancy measures of glucose and insulin. DESIGN, SETTING, AND PARTICIPANTS: Case-control study from a population-based cohort of 277 pregnant women in southern and central California carrying infants with tetralogy of Fallot (TOF) (n = 55), dextrotransposition of the great arteries (dTGA) (n = 42), or healthy infants without CHD (n = 180). Serum samples were collected from 2003 through 2007. The analysis was conducted from March through June 2015. MAIN OUTCOMES AND MEASURES: Blood analytes related to maternal glucose metabolism were measured from random nonfasting second-trimester blood samples. We measured serum insulin levels by a validated radioimmunoassay, and we measured glucose levels. Multivariable logistic regression models estimated the association between these levels and case status. RESULTS:Serum glucose values were elevated in the maternal samples for offspring with TOF (median, 97.0 mg/dL [to convert to millimoles per liter, multiply by 0.0555]) relative to controls (median, 91.5 mg/dL) (P = .01, Wilcoxon rank sum test), a phenomenon not observed in the maternal samples for offspring with dTGA (median, 90.0 mg/dL) relative to controls (P = .18, Wilcoxon rank sum test). Serum insulin levels were significantly different between controls (median, 18.8 μIU/mL [to convert to picomoles per liter, multiply by 6.945]) and maternal samples for offspring with dTGA (median, 13.1 μIU/mL; P = .048, Wilcoxon rank sum test) but not with TOF (median, 14.3 μIU/mL; P = .35, Wilcoxon rank sum test). Relative to maternal blood glucose levels of infants without cardiac malformations, we observed that maternal blood glucose levels in models including insulin were strongly associated with odds of TOF (adjusted odds ratio = 7.54; 95% CI, 2.30-24.69) but not with dTGA (adjusted odds ratio = 1.16; 95% CI, 0.28-4.79). CONCLUSIONS AND RELEVANCE: These results represent a direct correlation of glucose as a continuous variable to odds of specific cardiac malformations. The association between serum glucose and odds of TOF indicates the need for additional epidemiological and mechanistic investigations into the risk conferred by insulin signaling and glucose metabolism during early pregnancy.
Authors: Lukas A Lisowski; Paul M Verheijen; Joshua A Copel; Charles S Kleinman; Sander Wassink; Gerard H A Visser; Erik-Jan Meijboom Journal: Herz Date: 2010-02-09 Impact factor: 1.443
Authors: Jaana Lindström; Anne Louheranta; Marjo Mannelin; Merja Rastas; Virpi Salminen; Johan Eriksson; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: Claire E Schulkey; Suk D Regmi; Rachel A Magnan; Megan T Danzo; Herman Luther; Alayna K Hutchinson; Adam A Panzer; Mary M Grady; David B Wilson; Patrick Y Jay Journal: Nature Date: 2015-04-01 Impact factor: 49.962
Authors: Jessica A Marcinkevage; C J Alverson; K M Venkat Narayan; Henry S Kahn; Julia Ruben; Adolfo Correa Journal: Diabetes Care Date: 2013-06-18 Impact factor: 19.112
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Patrick Y Jay; Ehiole Akhirome; Rachel A Magnan; M Rebecca Zhang; Lillian Kang; Yidan Qin; Nelson Ugwu; Suk Dev Regmi; Julie M Nogee; James M Cheverud Journal: Mol Cell Endocrinol Date: 2016-08-20 Impact factor: 4.102
Authors: Emmi I T Helle; Preston Biegley; Joshua W Knowles; Joseph B Leader; Sarah Pendergrass; Wei Yang; Gerald R Reaven; Gary M Shaw; Marylyn Ritchie; James R Priest Journal: J Pediatr Date: 2017-12-15 Impact factor: 4.406
Authors: James R Priest; Kazutoyo Osoegawa; Nebil Mohammed; Vivek Nanda; Ramendra Kundu; Kathleen Schultz; Edward J Lammer; Santhosh Girirajan; Todd Scheetz; Daryl Waggott; Francois Haddad; Sushma Reddy; Daniel Bernstein; Trudy Burns; Jeffrey D Steimle; Xinan H Yang; Ivan P Moskowitz; Matthew Hurles; Richard P Lifton; Debbie Nickerson; Michael Bamshad; Evan E Eichler; Seema Mital; Val Sheffield; Thomas Quertermous; Bruce D Gelb; Michael Portman; Euan A Ashley Journal: PLoS Genet Date: 2016-04-08 Impact factor: 5.917